Actively Recruiting
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy
Led by Jonsson Comprehensive Cancer Center · Updated on 2025-06-22
102
Participants Needed
1
Research Sites
318 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This phase II trial investigates the effect of extremely hypofractionated intensity modulated stereotactic body radiotherapy in treating patients with prostate cancer that has rising prostate specific antigen (PSA) after radical prostatectomy. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects.
CONDITIONS
Official Title
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- History of confirmed prostate adenocarcinoma treated with radical prostatectomy
- Presence of one or more: adverse pathology features, rising PSA on at least two tests above 0.03 ng/mL, intermediate- or high-risk genomic score, or prostate cancer in one or more lymph nodes at surgery
- CT scan and MRI of the pelvis within 120 days before enrollment (MRI exemption allowed if needed)
- Bone scan or advanced imaging within 120 days before enrollment if PSA is above 1.0 ng/mL
- Age 18 years or older
- Karnofsky performance status 70 or higher and/or ECOG 0-2
- Ability to understand and sign informed consent
You will not qualify if you...
- Evidence of distant metastases (lymphadenopathy below renal arteries may be allowed)
- Neuroendocrine or small cell carcinoma of the prostate
- Prior pelvic radiotherapy
- History of Crohn's disease, ulcerative colitis, or ataxia telangiectasia
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States, 90095
Actively Recruiting
Research Team
B
Brian Carlton
CONTACT
V
Vince Basehart
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here